Results 41 to 50 of about 8,013 (194)

Phosphoglycerate Dehydrogenase: Potential Therapeutic Target and Putative Metabolic Oncogene [PDF]

, 2014
Exemplified by cancer cells' preference for glycolysis, for example, the Warburg effect, altered metabolism in tumorigenesis has emerged as an important aspect of cancer in the past 10–20 years.
Zogg, Cheryl K.
core   +3 more sources

Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis [PDF]

, 2010
Most tumors exhibit increased glucose metabolism to lactate, however, the extent to which glucose-derived metabolic fluxes are used for alternative processes is poorly understood [1, 2].
Adam J Bass, AL Richardson, Alexandra R Grassian, Andrea L Richardson, Atsuo T Sasaki, Azra H Ligon, CA Fernandez, CB Thompson, CH Eng, Christian M Metallo, Costas A Lyssiotis, Dimitrios Anastasiou, DJ Slamon, DK Nomura, DR Rhodes, Edouard Mullarky, G Bodenhausen, Gerhard Wagner, Gregory Heffron, Gregory Stephanopoulos, H Bismut, Hadar Sharfi, J Debnath, J Greshock, J Luo, Jason W Locasale, Joan S Brugge, John M Asara, JW Locasale, K Hara, K Hoek, K Snell, Katherine R Mattaini, L Tabatabaie, Lewis C Cantley, Lynda Chin, Matthew G Vander Heiden, Matthew Meyerson, MG Vander Heiden, MG Vander Heiden, Mika Sasaki, MR Antoniewicz, Natalie I Vokes, O Warburg, R Beroukhim, R Teperino, Rameen Beroukhim, RJ DeBerardinis, S Kit, S Pollari, Tamar Melman, Taru Muranen, TJ de Koning, W Lu, WD Foulkes, Y Achouri, ZT Schafer   +56 more
core   +1 more source

eIF3i promotes colorectal cancer cell survival via augmenting PHGDH translation

Journal of Biological Chemistry, 2023
Translational regulation is one of the decisive steps in gene expression, and its dysregulation is closely related to tumorigenesis. Eukaryotic translation initiation factor 3 subunit i (eIF3i) promotes tumor growth by selectively regulating gene translation, but the underlying mechanisms are largely unknown.
Yaguang Zhang, Xiaowen Wan, Xuyang Yang, Xueqin Liu, Qing Huang, Lian Zhou, Su Zhang, Sicheng Liu, Qunli Xiong, Mingtian Wei, Lei Qiu, Bo Zhang, Junhong Han   +12 more
openaire   +2 more sources

Can small molecular inhibitors that stop de novo serine synthesis be used in cancer treatment?

Cell Death Discovery, 2021
To sustain their malignancy, tumour cells acquire several metabolic adaptations such as increased oxygen, glucose, glutamine, and lipids uptake. Other metabolic processes are also enhanced as part of tumour metabolic reprogramming, for example, increased
Megan Jessica McNamee, David Michod, Maria Victoria Niklison-Chirou   +2 more
doaj   +1 more source

Cancer Cell Metabolism: One Hallmark, Many Faces [PDF]

, 2012
Cancer cells must rewire cellular metabolism to satisfy the demands of growth and proliferation. Although many of the metabolic alterations are largely similar to those in normal proliferating cells, they are aberrantly driven in cancer by a combination ...
Cantor, Jason R., Sabatini, David
core   +2 more sources

Genome-wide analyses identify common variants associated with macular telangiectasia type 2 [PDF]

, 2017
Idiopathic juxtafoveal retinal telangiectasis type 2 (macular telangiectasia type 2; MacTel) is a rare neurovascular degenerative retinal disease. To identify genetic susceptibility loci for MacTel, we performed a genome-wide association study (GWAS ...
A Bringmann, A Demirkan, A Kottgen, AC Barbosa, AC Len, AJ Mears, Anna Quaglieri, B Gold, B Howie, B Yu, BH Weber, C Giaume, C Toomes, Carolyn Cai, Catherine A Egan, CC Breugem, CC Chang, CW Carr, D Maiti, DA Bessant, EP Rhee, EY Chew, F Brancati, G Pare, G Tikellis, Global Lipids Genetics Consortium, GS Hageman, H Hao, I Eerola, I Eerola, J Bergeron-Sawitzke, J Raffler, J Raffler, J Yang, Jana Zernant, JB van Meurs, JD Cahoy, JDM Gass, JJ Chen, JR Black, JS Danik, K Mittelstrass, K Suhre, KT Oh, KZ Aung, L Bouchard, LA Lange, Lawrence A Yannuzzi, LC Kottyan, Lea Scheppke, LG Fritsche, LG Fritsche, Lisa Baird, LW Klomp, M Borenstein, M Henkemeyer, M Hong, M Sabater-Lleal, M Veiga-da-Cunha, M Zhao, M Zweier, Marcus Fruttiger, Mark Leppert, Martin Friedlander, MB Powner, MC Gillies, ME Kleber, ME Ritchie, Melanie Bahlo, MI Dorrell, MK Ikram, ML Summar, MR Metea, N Le Meur, N Revencu, N Siddiqui, NL Parmalee, NL Parmalee, Nori Matsunami, O Delaneau, P Artimo, Q Lin, Q Lin, R Klein, Rando Allikmets, RF Gariano, RJ Pruim, Roberto Bonelli, RS de Wijn, S Purcell, S Purcell, SH Chung, SH Lee, SR Hannan, SR Williams, SY Shin, T Illig, T Sing, T Watanabe, TD Gelehrter, TE Clemons, TE Clemons, Thomas S Scerri, TW Isaacs, U Menchini, V De Laurenzi, W Bi, W Wooderchak-Donahue, W Xie, WL Hutton, X Sim, Y Onishi, Y Usui, Z Xu   +113 more
core   +1 more source

High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer

Translational Oncology, 2016
Tumors have exceptionally high demands for energy and anabolism because of their rapid growth. The de novo serine synthesis pathway initiated by phosphoglycerate dehydrogenase (PHGDH) has been recognized as a hallmark of metabolic adaption in ...
Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang, Xiaoyu Zhou, Jiahai Shi   +7 more
doaj   +1 more source

Mitochondrial Phosphoenolpyruvate Carboxykinase Regulates Metabolic Adaptation and Enables Glucose-Independent Tumor Growth [PDF]

, 2015
Cancer cells adapt metabolically to proliferate under nutrient limitation. Here we used combined transcriptional-metabolomic network analysis to identify metabolic pathways that support glucose-independent tumor cell proliferation.
Artyomov, Maxim N., Avizonis, Daina, Blagih, Julianna, Bridon, Gaëlle, Choinière, Luc, Coelho, Paula P., Elder, Douglas J E, Flynn, Breanna R., Gingras, Marie Claude, Griss, Takla, Jones, Russell G., Loginicheva, Ekaterina, Ntimbane, Thierry, Pause, Arnim, Raissi, Thomas C., Samborska, Bozena, Sergushichev, Alexey, Tavaré, Jeremy M., Thomas, Elaine C., Vincent, Emma E.   +19 more
core   +2 more sources

Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer

Oncotarget, 2016
3-Phosphoglycerate dehydrogenase (PHGDH) has recently been identified as an attractive target in cancer therapy as it links upregulated glycolytic flux to increased biomass production in cancer cells. PHGDH catalyses the first step in the serine synthesis pathway and thus diverts glycolytic flux into serine synthesis.
Unterlass JE, Baslé A, Blackburn TJ, Tucker J, Turlais F, Cano C, Noble MME, Curtin NJ   +7 more
openaire   +3 more sources

PHGDH as a mechanism for resistance in metabolically-driven cancers

Cancer Drug Resistance, 2020
At the forefront of cancer research is the rapidly evolving understanding of metabolic reprogramming within cancer cells. The expeditious adaptation to metabolic inhibition allows cells to evolve and acquire resistance to targeted treatments, which makes therapeutic exploitation complex but achievable.
Rathore, Richa, Schutt, Charles R., Van Tine, Brian A.   +2 more
openaire   +3 more sources